糖尿病&肥満治療薬の開発パイプラインレビュー2016

【英語タイトル】Diabetes & Obesity Drug Development Pipeline Review, 2016

GBI Researchが出版した調査資料(DATA1122048)・商品コード:DATA1122048
・発行会社(調査会社):GBI Research
・発行日:2016年12月
・ページ数:560
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥439,450見積依頼/購入/質問フォーム
Site LicenseUSD7,990 ⇒換算¥878,900見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD11,985 ⇒換算¥1,318,350見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Diabetes & Obesity Drug Development Pipeline Review, 2016
Summary

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.

Scope

- Which companies are the most active within the pipeline for diabetes and obesity?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
- What are the most important R&D milestones and data publications to have occurred in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication.
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each.
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these.
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

【レポートの目次】

Table of Contents
Table of Contents 4
List of Tables 6
List of Figures 22
Diabetes and Obesity Report Coverage 24
Type 1 Diabetes (Juvenile Diabetes) Overview 24
Type 2 Diabetes Overview 24
Obesity Overview 24
Therapeutics Development by Stage 25
Type 1 diabetes (Juvenile Diabetes) 25
Type 2 Diabetes 27
Obesity 29
Therapeutics under Development by Companies 31
Type 1 Diabetes (Juvenile Diabetes) 31
Type 2 Diabetes 41
Obesity 61
Therapeutics under Investigation by Universities/Institutes 70
Type 1 diabetes (Juvenile Diabetes) 70
Type 2 Diabetes 72
Obesity 75
Pipeline Products Glance 78
Type 1 diabetes (Juvenile Diabetes) 78
Type 2 Diabetes 81
Obesity 84
Products under Development by Companies 87
Type 1 diabetes (Juvenile Diabetes) 87
Type 2 Diabetes 98
Obesity 121
Products under Investigation by Universities/Institutes 130
Type 1 diabetes (Juvenile Diabetes) 130
Type 2 Diabetes 133
Obesity 139
Companies Involved in Therapeutics Development 143
Type 1 diabetes (Juvenile Diabetes) 143
Type 2 Diabetes 196
Obesity 309
Therapeutics Assessment 361
Type 1 diabetes (Juvenile Diabetes) 361
Type 2 Diabetes 387
Obesity 440
Dormant Projects 462
Type 1 diabetes (Juvenile Diabetes) 462
Type 2 Diabetes 471
Obesity 495
Discontinued Products 509
Type 1 diabetes (Juvenile Diabetes) 509
Type 2 Diabetes 512
Obesity 521
Product Development Milestones 525
Type 1 diabetes (Juvenile Diabetes) 525
Type 2 Diabetes 537
Obesity 549
Appendix 559
Methodology 559
Coverage 559
Secondary Research 559
Primary Research 559
Expert Panel Validation 559
Contact Us 559
Disclaimer 560

List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 25
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 26
Number of Products under Development for Type 2 Diabetes, H2 2016 27
Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 28
Number of Products under Development for Obesity, H2 2016 29
Number of Products under Development for Obesity – Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 32
Number of Products under Development by Companies, H2 2016 (Contd..1) 33
Number of Products under Development by Companies, H2 2016 (Contd..2) 34
Number of Products under Development by Companies, H2 2016 (Contd..3) 35
Number of Products under Development by Companies, H2 2016 (Contd..4) 36
Number of Products under Development by Companies, H2 2016 (Contd..5) 37
Number of Products under Development by Companies, H2 2016 (Contd..6) 38
Number of Products under Development by Companies, H2 2016 (Contd..7) 39
Number of Products under Development by Companies, H2 2016 (Contd..8) 40
Number of Products under Development by Companies, H2 2016 42
Number of Products under Development by Companies, H2 2016 (Contd..1) 43
Number of Products under Development by Companies, H2 2016 (Contd..2) 44
Number of Products under Development by Companies, H2 2016 (Contd..3) 45
Number of Products under Development by Companies, H2 2016 (Contd..4) 46
Number of Products under Development by Companies, H2 2016 (Contd..5) 47
Number of Products under Development by Companies, H2 2016 (Contd..6) 48
Number of Products under Development by Companies, H2 2016 (Contd..7) 49
Number of Products under Development by Companies, H2 2016 (Contd..8) 50
Number of Products under Development by Companies, H2 2016 (Contd..9) 51
Number of Products under Development by Companies, H2 2016 (Contd..10) 52
Number of Products under Development by Companies, H2 2016 (Contd..11) 53
Number of Products under Development by Companies, H2 2016 (Contd..12) 54
Number of Products under Development by Companies, H2 2016 (Contd..13) 55
Number of Products under Development by Companies, H2 2016 (Contd..14) 56
Number of Products under Development by Companies, H2 2016 (Contd..15) 57
Number of Products under Development by Companies, H2 2016 (Contd..16) 58
Number of Products under Development by Companies, H2 2016 (Contd..17) 59
Number of Products under Development by Companies, H2 2016 (Contd..18) 60
Number of Products under Development by Companies, H2 2016 61
Number of Products under Development by Companies, H2 2016 (Contd..1) 62
Number of Products under Development by Companies, H2 2016 (Contd..2) 63
Number of Products under Development by Companies, H2 2016 (Contd..3) 64
Number of Products under Development by Companies, H2 2016 (Contd..4) 65
Number of Products under Development by Companies, H2 2016 (Contd..5) 66
Number of Products under Development by Companies, H2 2016 (Contd..6) 67
Number of Products under Development by Companies, H2 2016 (Contd..7) 68
Number of Products under Development by Companies, H2 2016 (Contd..8) 69
Number of Products under Investigation by Universities/Institutes, H2 2016 70
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 71
Number of Products under Investigation by Universities/Institutes, H2 2016 72
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 73
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 73
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 74
Number of Products under Investigation by Universities/Institutes, H2 2016 76
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 76
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 77
Comparative Analysis by Late Stage Development, H2 2016 78
Comparative Analysis by Clinical Stage Development, H2 2016 79
Comparative Analysis by Early Stage Development, H2 2016 80
Comparative Analysis by Unknown Stage Development, H2 2016 81
Comparative Analysis by Late Stage Development, H2 2016 81
Comparative Analysis by Clinical Stage Development, H2 2016 82
Comparative Analysis by Early Stage Development, H2 2016 83
Comparative Analysis by Unknown Stage Development, H2 2016 84
Comparative Analysis by Late Stage Development, H2 2016 84
Comparative Analysis by Clinical Stage Development, H2 2016 85
Comparative Analysis by Early Stage Development, H2 2016 86
Comparative Analysis by Unknown Stage Development, H2 2016 86
Products under Development by Companies, H2 2016 87
Products under Development by Companies, H2 2016 (Contd..1) 88
Products under Development by Companies, H2 2016 (Contd..2) 89
Products under Development by Companies, H2 2016 (Contd..3) 89
Products under Development by Companies, H2 2016 (Contd..4) 90
Products under Development by Companies, H2 2016 (Contd..5) 91
Products under Development by Companies, H2 2016 (Contd..6) 92
Products under Development by Companies, H2 2016 (Contd..7) 92
Products under Development by Companies, H2 2016 (Contd..8) 93
Products under Development by Companies, H2 2016 (Contd..9) 94
Products under Development by Companies, H2 2016 (Contd..10) 95
Products under Development by Companies, H2 2016 (Contd..11) 96
Products under Development by Companies, H2 2016 (Contd..12) 97
Products under Development by Companies, H2 2016 98
Products under Development by Companies, H2 2016 (Contd..1) 99
Products under Development by Companies, H2 2016 (Contd..2) 99
Products under Development by Companies, H2 2016 (Contd..3) 100
Products under Development by Companies, H2 2016 (Contd..4) 100
Products under Development by Companies, H2 2016 (Contd..5) 101
Products under Development by Companies, H2 2016 (Contd..6) 101
Products under Development by Companies, H2 2016 (Contd..7) 102
Products under Development by Companies, H2 2016 (Contd..8) 102
Products under Development by Companies, H2 2016 (Contd..9) 103
Products under Development by Companies, H2 2016 (Contd..10) 103
Products under Development by Companies, H2 2016 (Contd..11) 104
Products under Development by Companies, H2 2016 (Contd..12) 104
Products under Development by Companies, H2 2016 (Contd..13) 105
Products under Development by Companies, H2 2016 (Contd..14) 105
Products under Development by Companies, H2 2016 (Contd..15) 106
Products under Development by Companies, H2 2016 (Contd..16) 106
Products under Development by Companies, H2 2016 (Contd..17) 107
Products under Development by Companies, H2 2016 (Contd..18) 107
Products under Development by Companies, H2 2016 (Contd..19) 108
Products under Development by Companies, H2 2016 (Contd..20) 108
Products under Development by Companies, H2 2016 (Contd..21) 109
Products under Development by Companies, H2 2016 (Contd..22) 110
Products under Development by Companies, H2 2016 (Contd..23) 111
Products under Development by Companies, H2 2016 (Contd..24) 112
Products under Development by Companies, H2 2016 (Contd..25) 113
Products under Development by Companies, H2 2016 (Contd..26) 114
Products under Development by Companies, H2 2016 (Contd..27) 115
Products under Development by Companies, H2 2016 (Contd..28) 115
Products under Development by Companies, H2 2016 (Contd..29) 116
Products under Development by Companies, H2 2016 (Contd..30) 117
Products under Development by Companies, H2 2016 (Contd..31) 118
Products under Development by Companies, H2 2016 (Contd..32) 119
Products under Development by Companies, H2 2016 (Contd..33) 120
Products under Development by Companies, H2 2016 121
Products under Development by Companies, H2 2016 (Contd..1) 121
Products under Development by Companies, H2 2016 (Contd..2) 122
Products under Development by Companies, H2 2016 (Contd..3) 122
Products under Development by Companies, H2 2016 (Contd..4) 123
Products under Development by Companies, H2 2016 (Contd..5) 123
Products under Development by Companies, H2 2016 (Contd..6) 124
Products under Development by Companies, H2 2016 (Contd..7) 125
Products under Development by Companies, H2 2016 (Contd..8) 126
Products under Development by Companies, H2 2016 (Contd..9) 127
Products under Development by Companies, H2 2016 (Contd..10) 128
Products under Development by Companies, H2 2016 (Contd..11) 129
Products under Investigation by Universities/Institutes, H2 2016 130
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 131
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 132
Products under Investigation by Universities/Institutes, H2 2016 133
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 137
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 138
Products under Investigation by Universities/Institutes, H2 2016 139
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 140
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 141
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 142
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AbGenomics International, Inc., H2 2016 143
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Adocia, H2 2016 143
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AiCuris GmbH and Co KG, H2 2016 144
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Alteogen Inc., H2 2016 144
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 145
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ambrx, Inc., H2 2016 145
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AntriaBio, Inc., H2 2016 146
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aphios Corporation, H2 2016 146
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by APT Therapeutics, Inc., H2 2016 147
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 147
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Argos Therapeutics, Inc., H2 2016 148
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Artery Therapeutics, Inc., H2 2016 148
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Astellas Pharma Inc., H2 2016 149
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AstraZeneca Plc, H2 2016 149
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Athersys, Inc., H2 2016 150
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Atlantic Bio Sci LLC, H2 2016 150
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Axxam SpA, H2 2016 151
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Beta-Cell NV, H2 2016 151
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biocon Limited, H2 2016 152
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biogenomics Limited, H2 2016 152
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLineRx, Ltd., H2 2016 153
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLingus AG, H2 2016 153
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioTherapeutics Inc., H2 2016 154
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BirchBioMed Inc, H2 2016 154
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 155
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Caladrius Biosciences Inc, H2 2016 155
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 156
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Carlina Technologies SAS, H2 2016 156
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Compugen Ltd., H2 2016 157
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ConjuChem, LLC, H2 2016 157
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 158
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dance Biopharm Inc., H2 2016 158
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diabetology (Products) Ltd, H2 2016 159
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by DiaMedica Inc., H2 2016 159
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diamyd Medical AB, H2 2016 160
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 160
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 161
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Eli Lilly and Company, H2 2016 161
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by enGene, Inc, H2 2016 162
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ensol Biosciences Inc., H2 2016 162
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by EpiVax, Inc., H2 2016 162
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Escape Therapeutics, Inc., H2 2016 163
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Evotec AG, H2 2016 163
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 164
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Fate Therapeutics, Inc., H2 2016 164
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Generex Biotechnology Corporation, H2 2016 165
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GeNeuro SA, H2 2016 165
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Geropharm, H2 2016 166
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Gilead Sciences, Inc., H2 2016 166
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GlaxoSmithKline Plc, H2 2016 167
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Grifols, S.A., H2 2016 167
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Heptares Therapeutics Limited, H2 2016 168
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Iltoo Pharma, H2 2016 168
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ImmusanT, Inc., H2 2016 168
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Innopharmax Inc., H2 2016 169
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Intrexon Corporation, H2 2016 169
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Islet Sciences, Inc., H2 2016 170
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Johnson & Johnson, H2 2016 170
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kadimastem Ltd., H2 2016 171
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kamada Ltd., H2 2016 171
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kasiak Research Private Limited, H2 2016 172
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by KPI Therapeutics, Inc., H2 2016 172
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 173
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 173
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lonestar Heart, Inc., H2 2016 174
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MacroGenics, Inc., H2 2016 174
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medestea Research & Production S.p.A., H2 2016 175
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MedImmune LLC, H2 2016 175
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medy-Tox Inc., H2 2016 176
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Merck & Co., Inc., H2 2016 176
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Meridigen Biotech Co., Ltd., H2 2016 177
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MidaSol Therapeutics LP, H2 2016 177
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 178
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Novo Nordisk A/S, H2 2016 179
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Noxxon Pharma AG, H2 2016 180
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 180
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orgenesis Inc, H2 2016 181
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by OSE Immunotherapeutics, H2 2016 181
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 182
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Parvus Therapeutics, Inc., H2 2016 182
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pathfinder Cell Therapy Inc, H2 2016 183
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pfizer Inc., H2 2016 183
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaCyte Biotech, Inc., H2 2016 184
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaIN Corporation, H2 2016 184
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Prometheon Pharma, LLC, H2 2016 185
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 185
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by RedHill Biopharma Ltd., H2 2016 186
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by REGiMMUNE Corporation, H2 2016 186
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sanofi, H2 2016 187
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by SEKRIS Biomedical, Inc., H2 2016 187
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Selecta Biosciences, Inc., H2 2016 188
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Semma Therapeutics Inc., H2 2016 188
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sevion Therapeutics, Inc., H2 2016 189
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Strongbridge Biopharma plc , H2 2016 189
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Therapix Biosciences Ltd., H2 2016 190
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Thermalin Diabetes, LLC, H2 2016 190
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Toleranzia AB, H2 2016 191
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Transgene Biotek Limited, H2 2016 191
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by UCB SA, H2 2016 192
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Unicyte AG, H2 2016 192
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by United Therapeutics Corporation, H2 2016 193
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ViaCyte, Inc., H2 2016 193
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Visionary Pharmaceuticals, Inc., H2 2016 194
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XL-protein GmbH, H2 2016 194
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XOMA Corporation, H2 2016 195
Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 195
Type 2 Diabetes – Pipeline by Addex Therapeutics Ltd, H2 2016 196
Type 2 Diabetes – Pipeline by Adocia, H2 2016 196
Type 2 Diabetes – Pipeline by Advinus Therapeutics Ltd, H2 2016 197
Type 2 Diabetes – Pipeline by Aegis Therapeutics, LLC, H2 2016 197
Type 2 Diabetes – Pipeline by AFFiRiS AG, H2 2016 198
Type 2 Diabetes – Pipeline by Alize Pharma SAS, H2 2016 198

List of Figures
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 25
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 26
Number of Products under Development for Type 2 Diabetes, H2 2016 27
Number of Products under Development for Type 2 Diabetes – Comparative Analysis, H2 2016 28
Number of Products under Development for Obesity, H2 2016 29
Number of Products under Development for Obesity – Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Development by Companies, H2 2016 41
Number of Products under Development by Companies, H2 2016 61
Number of Products under Investigation by Universities/Institutes, H2 2016 70
Number of Products under Investigation by Universities/Institutes, H2 2016 72
Number of Products under Investigation by Universities/Institutes, H2 2016 75
Comparative Analysis by Late Stage Development, H2 2016 78
Comparative Analysis by Clinical Stage Development, H2 2016 79
Comparative Analysis by Early Stage Products, H2 2016 80
Comparative Analysis by Late Stage Development, H2 2016 81
Comparative Analysis by Clinical Stage Development, H2 2016 82
Comparative Analysis by Early Stage Products, H2 2016 83
Comparative Analysis by Late Stage Development, H2 2016 84
Comparative Analysis by Clinical Stage Development, H2 2016 85
Comparative Analysis by Early Stage Products, H2 2016 86
Assessment by Monotherapy Products, H2 2016 361
Assessment by Combination Products, H2 2016 362
Number of Products by Top 10 Targets, H2 2016 363
Number of Products by Stage and Top 10 Targets, H2 2016 363
Number of Products by Top 10 Mechanism of Actions, H2 2016 373
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 373
Number of Products by Top 10 Routes of Administration, H2 2016 383
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 383
Number of Products by Top 10 Molecule Types, H2 2016 385
Number of Products by Stage and Top 10 Molecule Types, H2 2016 385
Assessment by Monotherapy Products, H2 2016 387
Assessment by Combination Products, H2 2016 388
Number of Products by Top 10 Targets, H2 2016 389
Number of Products by Stage and Top 10 Targets, H2 2016 389
Number of Products by Top 10 Mechanism of Actions, H2 2016 410
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 410
Number of Products by Top 10 Routes of Administration, H2 2016 436
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 436
Number of Products by Top 10 Molecule Types, H2 2016 438
Number of Products by Stage and Top 10 Molecule Types, H2 2016 438
Assessment by Monotherapy Products, H2 2016 440
Assessment by Combination Products, H2 2016 441
Number of Products by Top 10 Targets, H2 2016 442
Number of Products by Stage and Top 10 Targets, H2 2016 442
Number of Products by Top 10 Mechanism of Actions, H2 2016 450
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 450
Number of Products by Routes of Administration, H2 2016 458
Number of Products by Stage and Routes of Administration, H2 2016 458
Number of Products by Top 10 Molecule Types, H2 2016 460
Number of Products by Stage and Top 10 Molecule Types, H2 2016 460

【レポートのキーワード】

糖尿病、肥満治療薬

★調査レポート[糖尿病&肥満治療薬の開発パイプラインレビュー2016] (コード:DATA1122048)販売に関する免責事項を必ずご確認ください。
★調査レポート[糖尿病&肥満治療薬の開発パイプラインレビュー2016]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆